A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...
Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.
In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...
Apixaban significantly reduces stroke risk in people with subclinical atrial fibrillation and prior stroke history.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback